Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › vericiguat

vericiguat

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of vericiguat

4 trials tracked of vericiguat: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 88 citations.

4Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 1
  1. Phase 3 A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) Completed · 88 cited
  2. Phase 3 A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) Completed · 57 cited
  3. Phase 4 The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation Completed
  4. Phase 2 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Vericiguat showed no significant effect on flow-mediated dilation in a small pilot trial of 26 heart failure patients
Cardiology RCT
Vericiguat showed no significant effect on flow-mediated dilation in a small pilot trial of 26 heart failure patients Pilot trial shows vericiguat may lower heart failure blood pressure markers
This pilot, randomized, double-blind, placebo-controlled trial enrolled 26 patients with heart failure with reduced ejection fraction (HFrEF…
A small pilot trial found vericiguat reduced a heart failure blood pressure marker, though the study was too small to confirm this benefit.
May 1, 2026
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
Drug Pipeline Sys. Review
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications Meals May Not Matter for Most New Heart and Diabetes Pills
This PRISMA scoping review synthesized data from 36 publications regarding food-drug interactions in cardiovascular and diabetic medications…
Most new heart and diabetes pills work the same whether you take them with food or on an empty stomach, but a few still need timing.
Frontiers Apr 27, 2026